202 related articles for article (PubMed ID: 21343576)
21. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
[No Abstract] [Full Text] [Related]
22. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
23. Sorafenib for advanced hepatocellular carcinoma: a systematic review.
Ling-lin Z; Li M; Jin-hui T; Ke-hu Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):51-7. PubMed ID: 21375938
[TBL] [Abstract][Full Text] [Related]
24. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib for the treatment of advanced hepatocellular carcinoma.
Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
[TBL] [Abstract][Full Text] [Related]
26. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
27. Selection of patients with hepatocellular carcinoma for sorafenib.
Abou-Alfa GK
J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
29. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
30. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
32. Developing better treatments in hepatocellular carcinoma.
Duffy A; Greten T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
[TBL] [Abstract][Full Text] [Related]
33. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
[TBL] [Abstract][Full Text] [Related]
34. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
[TBL] [Abstract][Full Text] [Related]
35. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
Welker MW; Lubomierski N; Gog C; Herrmann E; Engels K; Vogl TJ; Bechstein WO; Zeuzem S; Trojan J
J Chemother; 2010 Jun; 22(3):205-11. PubMed ID: 20566428
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
[No Abstract] [Full Text] [Related]
39. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Carr BI; Carroll S; Muszbek N; Gondek K
J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
